$CODX CoDiagnostics should have much greater marketshare at this point in the pandemic... We were the first to get FDA approval and basically gave up our first-mover advantage. With that said, there is still so much potential if we play the cards right. There will be enormous sums of money allocated for COVID-testing in the upcoming stimulus bills and CODX needs to have lobbyists touting our virtues to congress right now. There is no reason why our tests cannot become the dominant PCR test as the vaccine is rolled out throughout the world. Congress will be spending billions on COVID-testing. How much of that will be ours?
8 Likes